A Phase 3 interventional study of RABEPRAZOLE SODIUM and RABEPRAZOLE SODIUM in Non-erosive Gastroesophageal Reflux Disease, sponsored by Eisai Inc.. Completed at 13 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2011-10-05.
Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing rabeprazole in Gastroesophageal Reflux — none open to participants now, none under way, none of them phase 3. Rabeprazole · Gastroesophageal Reflux.
Among the 40 studies testing rabeprazole in Gastroesophageal Reflux, this one is the 34th largest by enrollment of the 39 interventional ones that give a count, is one of 7 that started in 2005, is one of 16 in phase 3, and was the 3rd registered.
1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.
Browse Gastroesophageal Reflux studies →None of the 40 studies testing rabeprazole in Gastroesophageal Reflux is open now. The open studies under Gastroesophageal Reflux, anywhere →
Rabeprazole: first FDA approval 1999 (ACIPHEX). What it is approved for, and how studies give it, is on its page →
Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 5 · Phase 3 17 · Phase 4 8
First in 2001; this study’s year is marked. 7 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 68 across 799 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 100 across the 39 interventional studies. Of the 38 that completed or were terminated, 15 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 40 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
13 studies in Gastroesophageal Reflux by Eisai Co., Ltd.: none open now, none under way, none of them phase 3. Of 13 finished, 12 (92%) have results posted.
Among the 13 studies in Gastroesophageal Reflux by Eisai Co., Ltd., this one is the 13th largest by enrollment, is one of 2 that started in 2005, is one of 9 in phase 3, and was the 2nd registered.
Eisai Co., Ltd.’s Gastroesophageal Reflux studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 40 studies testing rabeprazole in Gastroesophageal Reflux, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eisai Co., Ltd.’s 13 in Gastroesophageal Reflux:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To investigate esophageal reflux condition in patients with non-erosive gastroesophageal reflux disease by assessing with a 24-hour esophageal pH monitoring or effects of a 4-week treatment with 5 mg/day or 10 mg/day of E3810 (Pariet (Rabeprazole Sodium)).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The patients to be included will be outpatients who meet all of the following criteria. No specific gender is asked.
\<For the observation period>
\<For the treatment period>
Exclusion Criteria:
Patients who meet any of the following criteria will be excluded from the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: RABEPRAZOLE SODIUM
Drug: RABEPRAZOLE SODIUM
rabeprazole sodium 5 mg: once daily orally for 4 weeks
rabeprazole sodium 10 mg: once daily orally for 4 weeks
The Percent Time With pH <4.0 During 24 Hour Esophageal pH Monitoring at the End of the Observation Period (Predose Monitoring) and at the End of the Treatment Period (Postdose Monitoring).
Mean and standard deviation of percent time pH\<4.0 on 24 hour esophageal pH monitoring.
Time frame: Baseline and 4 weeks
This study was recruited at 13 centers in Japan during the period of May-2005 to Oct-2005.
| Milestone | E3810 Pariet (Rabeprazole Sodium) 5 mg | E3810 Pariet (Rabeprazole Sodium) 10 mg |
|---|---|---|
| Started | 13 | 13 |
| Completed | 13 | 12 |
| Not completed | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
Mean and standard deviation of percent time pH\<4.0 on 24 hour esophageal pH monitoring.
| Percent Time | E3810 Pariet (Rabeprazole Sodium) 5 mg | E3810 Pariet (Rabeprazole Sodium) 10 mg |
|---|---|---|
| Baseline | 6.72 ± 5.30 | 7.03 ± 4.76 |
| 4 weeks | 1.38 ± 0.79 | 0.87 ± 1.22 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| E3810 Pariet (Rabeprazole Sodium) 5 mg | — | 0/13 (0%) | 6/13 (46.2%) |
| E3810 Pariet (Rabeprazole Sodium) 10 mg | — | 0/13 (0%) | 10/13 (76.9%) |
| Event | E3810 Pariet (Rabeprazole Sodium) 5 mg | E3810 Pariet (Rabeprazole Sodium) 10 mg |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/13 | 1/13 |
| HeadacheNervous system disorders | 1/13 | 2/13 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/13 | 2/13 |
| NauseaGastrointestinal disorders | 2/13 | 0/13 |
| CellulitisInfections and infestations | 0/13 | 1/13 |
| NasopharyngitisInfections and infestations | 0/13 | 1/13 |
| Tympanic membrane perforationEar and labyrinth disorders | 0/13 | 1/13 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/13 | 1/13 |
| Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders | 0/13 | 1/13 |
| Abdominal distensionGastrointestinal disorders | 1/13 | 1/13 |
| Age Continuous(years) | E3810 Pariet (Rabeprazole Sodium) 5 mg | E3810 Pariet (Rabeprazole Sodium) 10 mg | Total |
|---|---|---|---|
| Mean | 40.6 ± 20.0 | 42.7 ± 15.8 | 41.6 ± 17.5 |
| Sex: Female, Male(Participants) | E3810 Pariet (Rabeprazole Sodium) 5 mg | E3810 Pariet (Rabeprazole Sodium) 10 mg | Total |
|---|---|---|---|
| Female | 3 | 4 | 7 |
| Male | 6 | 5 | 11 |
| Race (NIH/OMB)(Participants) | E3810 Pariet (Rabeprazole Sodium) 5 mg | E3810 Pariet (Rabeprazole Sodium) 10 mg | Total |
|---|---|---|---|
| Asian | 9 | 9 | 18 |
| Region of Enrollment(participants) | E3810 Pariet (Rabeprazole Sodium) 5 mg | E3810 Pariet (Rabeprazole Sodium) 10 mg | Total |
|---|---|---|---|
| Japan | 9 | 9 | 18 |
The record gives a start of May 2005, a primary completion of Oct 2005 and a completion of Oct 2005. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2011, 6 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rabeprazole